bluuebunny/crossref_metadata_2025_split huggingface dataset:
Sociodemographic and clinicopathologic factors of triple negative breast cancer at an academic urban safety-net hospital.
Authors: Wang Judy Jiaqi , Beaulieu-Jones Brendin , Acevedo Jose , Oshry Lauren , Merrill Andrea , Cassidy Michael Ryan , Ko Naomi Yu 
Published: June 2023

1090 Background: Racial disparities in breast cancer in the United States is a persistent and ongoing problem. Decades of research is derived from large population based data sets and little is published with granular detail of specific, actionable factors to target for interventions. From a large urban safety-net hospital, we evaluate sociodemographic and clinicopathologic factors on survival outcomes of triple negative breast cancer. Methods: We conducted a single-institution retrospective study of patients with invasive breast cancer, diagnosed and treated between January 2010 and December 2021 at an academic safety-net hospital where insurance systems allow for access and treatment for all patients. Demographic, tumor and treatment characteristics were obtained. Chi-square and ANOVA were used to examine associated factors among White, Black, and other races. Survival was analyzed using the Kaplan-Meier estimator and log-rank test. Significant risk factors were identified with Cox regression analysis. Results: 251 women with invasive triple negative breast cancer were diagnosed and treated during the study period. Median age was 58 years, 68.9% were non-white, and 64.9% were publicly insured or uninsured patients. Median time from diagnosis to treatment initiation was 29 days and follow up period was 1392 days. Having a non-English primary language and living in areas with lower socioeconomic indices are observed in non-White patients (P=0.003, 0.033) and predictive of a higher clinical stage at presentation (P=0.011, 0.021). Black patients were diagnosed at higher histologic grade (Black: 82.4%, White: 79.7%; P=0.003) and White patients were more likely to change facility during the treatment course (White: 32.4%, Black: 16.03%; P=0.005). No significant racial disparities were observed in time to treatment, recurrence rate, and overall survival. Among patients indicated for adjuvant therapies, including chemotherapy, immunotherapy, and radiation, rates of recommendation and completion of therapy did not vary by race. Five year survival did not significantly vary by race when adjusted for demographic and clinicopathologic factors. Conclusions: At an academic urban safety-net hospital where access to diagnostic and treatment resources are comparable across patient populations, no racial disparities were seen in treatment, recurrence, and survival outcomes. Further research on racial differences in breast cancer biology and health behaviors may improve understanding of triple negative disease or mitigate later stage diagnosis.
Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.
Authors: Ma Fei , Qiu Fuming , Tong Zhongsheng , Wang Jiani , Tan Yinuo , Bai Rui , Zhou Qing , Xing Xiaoyan 
Published: June 2023

1100 Background: ESG401 is an innovative ADC composed of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to topoisomerase I inhibitor SN-38 via a proprietary stable-cleavable linker with DAR of 8. Methods: Patients (pts) aged ≥18 years with locally advanced/metastatic solid tumors refractory to/relapsed from standard treatment with measurable disease (RECIST v1.1) were eligible. ESG401 is administered intravenously by designated dose and regimen until unacceptable toxicity or progressive disease. The Bayesian Optimal Interval (BOIN) design was used to establish the MTD. Results: As of Feb 3, 2023, 35 pts with a median age of 53 were treated with ≥1 dose of ESG401 during escalation at doses of 2-20 mg/kg once Q3W (Regimen A), or 12-16 mg/kg D1,8,15 in a 4-week cycle (Regimen B). 80% of pts were ECOG = 1, 63% of pts were 3L+; median 4 (2-10) prior lines, 94% of pts had visceral metas (11% brain, 63% liver, 60% lung) at baseline. Only one patient treated with 20 mg/kg experienced DLT. The MTD has not reached either regimen. The most common TRAEs were leukopenia (80%), neutropenia (69%), anemia (66%), fatigue (54%), nausea (51%), and vomiting (46%). The most common ≥ Grade 3 TRAEs were leukopenia (29%) and neutropenia (31%). There was no ≥ Grade 3 thrombocytopenia, diarrhea, skin rash, or oral mucositis. No Interstitial Lung Disease (ILD) was observed. Of 33 efficacy evaluable (EE) pts, 12 partial responses (PR) were observed and 4 pts had achieved SD ≥24 wks. The first dose level found PR (16 mg/kg Q3W) and afterward were taken as therapeutically relevant doses (TRD). The ORR and DCR were 36% (4/11) and 64% (7/11) in 11 TRD pts with TNBC, while 62% (8/13) and 77% (10/13) in 13 TRD pts with HR+/HER2-BC. Two pts with brain metas both got an obvious intracranial response (one pt whose intracranial lesion was significantly reduced to too small to measure). Until the cut-off date, 11 (31%) pts remained on treatment. Three pts were treated over 12 mons and the longest on-treatment duration was 12.9 mons. One pt had consistent PR up to 10.8 mons. Conclusions: The preliminary data demonstrated that ESG401 is safe and well-tolerated with promising signals of efficacy in heavily pretreated pts. These encouraging findings warrant further clinical evaluation. Clinical trial information: NCT04892342 . [Table: see text]
The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.
Authors: MacDuffie Emily , Lee Anna , Kuczmarska-Haas Aleksandra , Dalwadi Shraddha , Gillespie Erin F. , Ludwig Michelle Suzanne , Holliday Emma , Chino Fumiko 
Published: June 2023

11001 Background: Women in medicine are often in training during their peak fertility years. Many women defer childbearing until after training due to career concerns; in consequence, female physicians experience a higher rate of infertility than the general population. Experiences of infertility among female physicians and attitudes towards fertility preservation have not been well described. Methods: A novel 39 question survey was designed after comprehensive literature review to collect cross-sectional data on attitudes toward family planning and utilization of assisted reproductive technology (ART) among self-identified US female oncologists of all career levels. Descriptive statistics summarized frequencies of responses. Results: A total of 1005 responses were collected from female oncologists, of which 811 (81%) were attending/practicing physicians and 194 (19%) were trainees (192 residents/fellows and 2 medical students). 32% reported experiencing infertility. Of these 318 women, 9% reported no out-of-pocket expenses for ART while 39% spent more than $10,000 and 20% spent ≥$30,000. Side effects from infertility treatment required missing work for 22% and another 25% suffered mental health concerns related to infertility. Elective cryopreservation of eggs or embryos was reported by 6% of attendings and 4% of trainees. Among the 25 attendings who reported plans/desire to undergo fertility preservation in the future, most (76%) were unsure of feasibility. This was similarly reported in 72% of the 32 trainees with plans/desire to pursue fertility preservation. More trainees than practicing physicians (73% vs 65%) felt that fertility preservation should be discussed during medical training. Similarly, more trainees than attendings (58% vs 47%) felt that fertility concerns have a negative influence of their decision on when to start a family. While only 5% of all respondents reported using fertility preservation, an additional 6% were planning/considering using it and 21% felt that it would have benefitted them had it been available and affordable during training. Of the group that felt it would have been beneficial, 52% had experienced infertility. Conclusions: A third of surveyed female oncologists report experiencing infertility. Those that seek reproductive assistance can incur significant out of pocket costs with treatment related effects that can disrupt work or cause mental health concerns. Although fertility preservation was used by very few, one in five felt it could have been helpful to them if it was available and affordable. These results underscore the need to better support women in medicine to reduce the impact of infertility for female oncologists.
Workplace sexual harassment in academic oncology.
Authors: Yerramilli Divya , Williams Vonetta Michelle , Pandya Sankalp , Dandar Valerie M , Odei Bismarck , Chino Fumiko 
Published: June 2023

11003 Background: Research has shown workplace sexual harassment (WSH) is a pervasive problem in academia, affecting recruitment, retention & career advancement of women faculty. This study examines WSH in academic oncology faculty in a national survey. Methods: We obtained data from the Association of American Medical Colleges StandPoint Faculty Engagement Survey between 2020-22 representing a national sample of academic faculty from 25 medical schools (overall response rate (RR) 58%). WSH was considered specific “unwanted behavior” by coworkers that occurred at least once in the past year. Reporting questions were asked on a 5-point Likert Scale from Strongly Disagree to Strongly Agree, with 6th option “I Don’t Know.” Responses were grouped as Agree/Strongly Agree vs all others. Chi-square tested for differences by gender and race/ethnicity. Results: 807/1,287 oncologists participated in the survey (RR 63%), and 91% (731) answered the WSH questions. Most self-identified as men (58%) and only 8% identified as underrepresented race/ethnicity (URiM). See Table for findings. In oncology, women experienced any WSH at higher rates than men (33.1% vs 10.3%, p=0.001). The most common was derogatory comments due to gender. Regardless of gender, most knew how to report WSH incidents, but men were more likely to feel safe reporting. While 64.9% of men felt confident that their medical school would resolve WSH incident(s) effectively, only 48.7% of women did. Positive perceptions of reporting decrease among those who reported harassment. URiM faculty (35.6% vs.18.5%, p=0.001) were more likely than non-URiM faculty to experience at least one of the five harassment behaviors, although this was limited by small sample. Conclusions: In academic oncology, women and URiM experience workplace sexual harassment more often than men and non-URiM. Less than half of women felt confident that reporting an incident would lead to effective resolution. Urgent intervention is needed to combat the negative force of sexual harassment on workforce equity. [Table: see text]
Actionability of comprehensive genomic profiling compared to the tissue-based and plasma-based assay in patients with metastatic breast cancer: A real-world study.
Authors: Tada Hiroshi , Yasuda Jun , Shirota Hidekazu , Miyashita Minoru , Harada-shoji Narumi , Hamanaka Yohei , Ebata Akiko , Sato Miku , Ishida Takanori 
Published: June 2023

1101 Background: Comprehensive genomic profiling (CGP) was officially approved in August 2021 in Japan under the national health insurance system with three CGP tests in June 2019: FoundationOne CDx (F1CDx), OncoGuide NCC Oncopanel (NCC), which are tissue-based assay (TBA), and FoundationOne Liquid CDx (F1LCDx, starting in August 2021) which is plasma-based panel (PBA). The Center for Cancer Genomics and Advanced Therapeutics (C-CAT) has collected genomic and clinical data of 2,617 Japanese breast cancer patients as of October 2022. Here we assess these PBA and TBA to detect pathogenic or driver alterations informative for matched therapy in patients with metastatic breast cancer (mBC). Methods: We queried consecutive mBC patient clinical-genomic data through the C-CAT Research-Use Portal from June 2019 to October 2022 were categorized based on PBA or TBA. We used ClinVar to identify if the called somatic alterations were pathogenic or likely pathogenic, and BoostDM (https://www.intogen.org/boostdm/search) to identify potential driver mutations of breast cancer. The proposed rate of matched therapy was determined. The incidence rates were compared using the Pearson χ2 test. Results: Of 2,617 pts who underwent the CGP test, 2,259 (86%) received TBA (74% F1CDx and 12% NCC). The proportion of pts with ≥1 pathogenic variant with PBA and TBA was not significant (71.5%vs.72.7%; p=0.88), but the proportion of pts with ≥1 driver mutation was significantly higher with PBA than TBA (75.4% vs. 69.8%; p = 0.03). Regarding the proportion of pts who matched therapy or clinical trials presented among the pts for whom data were available, PBA was significantly lower than TBA (27.7% vs.38.5%, p < 0.001). Although data on post-treatment is still being collected, the proportion of tested patients that received matched therapies recommended by molecular tumor boards of each institute was significantly lower for PBA (4.2%vs. 8.3%; p = 0.007). Conclusions: This study is the first analysis of CGP for mBC in Japan using the C-CAT utilization program. Although significant alterations were well-detected in PBA, the proportion of pts who received matched-therapy post-testing was low for PBA. Possible causes include that PBA has fewer companion diagnoses than TBA in Japan and that PBA is more often used in later lines.
Addressing resiliency and burnout: A quantitative needs assessment of oncology physician assistants (PAs).
Authors: Tetzlaff Eric Daniel , Hylton Heather Marie , Ruth Karen J , Hasse Zachary , Hall Michael J. 
Published: June 2023

11016 Background: Significant progress has been made in understanding the factors associated with oncology (onc) PA burnout. However, little is known about what PAs need to mitigate burnout, the availability of resources, and barriers to interventions. Methods: A national survey of onc PAs was conducted in 2022. PAs completed a quantitative needs assessment to determine the importance of and their perceived skills in topics of self-care, clinical care, and professional development. For importance, “high importance” included ratings of ‘Essential’ or ‘Very Important’; for perceived skill, “high skill” included ratings of ‘Excellent’ or ‘Good’. Engagement with employee assistance programs (EAPs) was examined. Resiliency & Burnout were assessed using the Connor-Davidson Resilience Scale & the Maslach Burnout Inventory. Results: PAs (n = 171) were mostly practicing in medical oncology (66%) and outpatient (66%). The high importance topics most often identified were dealing with difficult patients (93%), dealing with difficult providers (89%), delivering bad news (88%) and coping with death / patient suffering and personal grief (86%). Topics less often reported as high importance included opportunities to be a mentor (61%), professional coaching (59%) and mindfulness skills (53%). PAs frequently reported high skills in dealing with difficult patients (75%), delivering bad news (72%), and resiliency skills (59%). Fewer PAs reported high skills for debriefing following significant events (49%) and mindfulness skills (42%). Burnout (BO) rates were higher for those with lower perceived skills in resiliency (p = 0.03) and dealing with difficult providers and staff (p = 0.03) but did not differ based on importance of any topics. Resiliency significantly increased with increasing levels of reported importance for the mindfulness skills training, cognitive skills training, and debriefing after significant events topics. Resiliency significantly increased with increased levels of perceived skill for all topics explored. Common barriers to well-being EAP participation were lack of time (58%) and concerns about confidentiality and stigma (26%). For PAs with concerns about stigma, resiliency scores were lower (6.4 vs 7.0; p < 0.001) and BO rates were higher (73% vs 47%; p = 0.005). Conclusions: Perceived deficiencies in resiliency training and managing difficult work relationships correlate with higher rates of burnout in onc PAs. Barriers to participation in EAPs, which may help address these deficits, are common and when present are associated with an alarming rate of burnout and lower resiliency. Cultural change in medicine is needed to reduce perceived and experienced stigmatizing experiences to address burnout. These findings suggest that burnout interventions which focus on building resiliency and managing work relationships are crucial and may be best implemented outside of the workplace.
Characterizing imposter syndrome among oncologists on social media.
Authors: Teplinsky Eleonora , Beltran Ponce Sara , Dizon Don S. , Florez Narjust , Katz Matthew S. , McAlarnen Lindsey Allison , Moerdler Scott , Murphy Martina Cathryn , Saeed Hina , Barry Maura Meredith 
Published: June 2023

11018 Background: Imposter syndrome (IS) is defined as an inability to believe that one’s success is deserved. It is commonly encountered by physicians, with cited statistics ranging from 22% to 98%, is associated with negative mental health impacts and can be harmful to one’s wellbeing. Given increasing SM use in hematology/oncology (H/O), we aimed to evaluate the effect of SM on IS among oncology trainees and oncologists. Methods: An anonymous online survey was distributed to oncology trainees and oncologists through SM platforms (Twitter, Facebook (FB), Instagram (IG)) and e-mail. Questions included demographics, current SM use, a novel scale for IS on SM (Table), Young Imposter Syndrome (YIS) Scale (a validated IS instrument) & assessment of mental health impacts of SM. Results: Out of 195 respondents, 103 answered all questions; median age 40y (27-65), 81% female. 21% were trainees and 36%, 30%, and 12% were early, mid and late-career faculty, respectively. Specialties included: adult H/O (72%), gynecologic oncology (11.3%), radiation oncology (10.5%), surgical oncology (4.1%), and pediatric H/O (1.5%). Twitter was the most commonly used SM platform (68%) followed by FB (36%) & IG (20%). 26% utilized professional SM 0-1 times/week while 28% did so daily. 97/157 (62%) noted positive mental health impacts from SM. 41% felt anxious, lonely or depressed due to SM. 19.7% have experienced SM harassment or cyberbullying. More than 50% of respondents met criteria on the YIS and IS scale; indeed, the YIS and IS on SM Scales were significantly correlated with each other (r = 0.57, p < 0.001, N = 103). The presence of IS on SM was associated with gender but not race/ethnicity or career stage. 59% of females versus 28% of males met criteria for IS (p = 0.02). The presence of IS on SM was significantly associated with self-perceived IS in professional settings (p < 0.001), but not in personal settings (p = 0.21). Conclusions: Many oncology professionals experienced IS while interacting on SM, but also note a positive mental health impact with SM use. The presence of IS on SM correlated with results on the YIS Scale, suggesting a novel assessment method, but further validation is needed. Future efforts to combat IS on SM while enhancing positive aspects of medical SM are warranted. [Table: see text]
Impact and engagement of a virtual platform to provide equitable oncology education globally.
Authors: Leyfman Yan , Pawar Shubhadarshini , Joshi Muskan , Balasubramanian Maduri , Wilkerson William B. , Menon Gayathri P. , Van de Kieft Alexandra , Jackewicz Sean , Abbas Rabab H. , Park Chandler H. 
Published: June 2023

11019 Background: Social media has emerged as a powerful outlet for the dissemination of medical information, especially in resource-limited regions, due to its mass global reach. However, misinformation has presented an unexpected detriment to public health on a global scale. To address this, MedNews Week (MNW), a free, virtual educational platform streamed on most social media platforms was developed to provide global oncology education through biweekly programming. Its leading show, Keynote Conference, features live virtual presentations from oncology’s premier global leaders discussing the latest developments in the field before a mainstream global audience. The aim of this study was to assess the worldwide reach and impact of this cost-free, virtual oncology education platform. Methods: From January 2022 to February 2023, MNW hosted 33 global leaders as Keynote Speakers discussing the latest developments in oncology. Viewership, impressions, and outreach data were collected from MNW’s social media accounts and Tweepmaps. Data was analyzed to assess MNW’s global reach and engagement and stratified based on engagement sentiment, gender, age group, and occupation. Results: During this period, MNW produced a healthcare social grasp score of 64% and generated over 64,000 Twitter impressions engaging 1.9 million viewers over 13 months in the US, UK, Ireland, India, France, and 16 lower socioeconomic (SE) countries and 99 cities. Most of the followers were from non-healthcare fields with more males than females (Table). Those who engaged conveyed positive sentiments (64%) contributing to a viewership increase from 47,589 (6 months) to 61,539 (1 year), where 60% of the audience was found to originate from lower SE regions globally. Conclusions: MNW has demonstrated an ability to attract and sustain a diverse, global, growing mainstream audience. Given MNW’s continued growth, it provides a proof-of-concept model to engage and disseminate medical information to mainstream audiences. The platform’s ability to showcase global leaders to mainstream audiences gratuitously, especially in lower SE regions that have been historically underserved, offers a practical approach to combat educational inequity. Consequently, such a platform has demonstrated great potential to positively impact global oncology education. Demographics of MedNews Week’s audience. [Table: see text]